PsyAccess
Spravato®Registry-verifiedDesignated-centers model

Universitäre Psychiatrische Dienste Bern (UPD)

Bern, Switzerland

Treatment & access

  • Treatments offeredesketamine (Spravato)
  • Access routepublic_reimbursed
  • Price informationReimbursed by mandatory health insurance (OKP/AOS) per SL Limitatio
  • ReimbursementBAG Spezialitätenliste Limitatio: cantonal psychiatric care mandate required; list valid 2025-10-01 to 2028-09-30 How reimbursement works in Europe →
  • Phone+41 31 930 91 11
  • Websitehttps://www.upd.ch/

About this provider

Universitäre Psychiatrische Dienste Bern (UPD) is the university psychiatric hospital for the Bern capital region, based at Bolligenstrasse 111. Its KIPAP competence centre (Zentrum Neuropsychiatrie) specialises in treatment-resistant depression, catatonia and neuropsychiatric illness, offering inpatient, day-clinic, outpatient and consultative care. UPD describes individualised treatment plans that combine disorder-specific psychotherapy, medication and modern brain-stimulation procedures, and it explicitly lists intranasal esketamine and intravenous ketamine among the newer treatment options for treatment-resistant depression.

Services & programs

  • KIPAP competence centre (Zentrum Neuropsychiatrie) for treatment-resistant depression
  • Intranasal esketamine and intravenous ketamine for treatment-resistant depression
  • Brain-stimulation procedures
  • Inpatient interventional psychiatry ward
  • Inpatient, day-clinic, outpatient and consultative adult psychiatry
  • Individualised treatment plans combining psychotherapy and medication

Common questions

How is esketamine treatment accessed at UPD Bern?

UPD's KIPAP centre treats treatment-resistant depression and lists intranasal esketamine among its procedures. Access to the Swiss Spravato route runs through a psychiatrist, who confirms the eligibility criteria and obtains the health insurer's cost approval (Kostengutsprache) before the first dose.

Who qualifies for reimbursed Spravato in Switzerland?

Basic insurance (OKP) covers it under a Limitatio: adults 18-74 whose current episode has not responded to at least two antidepressants plus one augmentation attempt, with CGI-S severity of 5 or more, insurer pre-approval before the first dose, and a maximum of 10 months of treatment.

Looking at alternatives? One of the BAG-designated Spravato centers; see the country guide and the limited-medical-use PAT program.

Verification

This record was taken directly from an official registry or program list and is re-checked on a rolling cadence.

Spotted an error? See our methodology for how records are checked and how to report a correction.